FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, prospective phase Ⅱ trial.

Category Primary study
ConferenceASCO ANNUAL MEETING
Year 2025
This article has no abstract
Epistemonikos ID: 2e136aaee573f53df3c3fd03927ee35f82f2fa84
First added on: Apr 04, 2026